Search Results: Treatment + Ovarian Cancer (4 results)

The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations. 

This study will test how safe and effective the immunotherapy drug Olvi-Vec is, when it is followed by further chemotherapy and the drug bevacizumab in women diagnosed with platinum-resistant or platinum-refractory ovarian, fallopian tube or primary peritoneal cancer.

This study will test the safety and effectiveness of the drug sovilnesib in patients with ovarian cancer.

This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine.